Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects ≥ 18 and ≤ 75 years of age~2. Provision of written informed consent for tumor resection, stereotactic surgery, tumor biopsy, samples collection and treatment with investigational products prior to undergoing any study procedures~3. Histologically confirmed supratentorial glioblastoma or other WHO grade III or IV malignant glioma from archival tissue.~4. Evidence of tumor recurrence/progression by MRI (RANO criteria) post standard initial therapy.~5. Previous standard of care anti-tumor treatment including surgery and/or biopsy and chemoradiation. The washout periods from prior therapies are intended as follows:~   1. Nitrosoureas: 6 weeks~  2. Other cytotoxic agents: 4 weeks~  3. Anti-angiogenic agents including bevacizumab: 4 weeks~  4. Targeted agents including small-molecule tyrosine kinase inhibitors: 2 weeks~  5. Experimental immunotherapies: 3 months~  6. Vaccine based therapy: 3 months~6. Able to undergo standard MRI scans with contrast agent~7. Karnofsky Performance Status ≥ 70~8. Adequate bone marrow reserves and liver and kidney function, as assessed by the following laboratory requirements:~   1. Hemoglobin ≥ 9 g/L~  2. Lymphocytes \> 500/ mm3~  3. Absolute Neutrophil Count ≥ 1500/ mm3~  4. Platelets ≥ 100,000/ mm3~  5. Serum creatinine ≤ 1.5 x ULN~  6. AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN. For subjects with documented liver metastases, ALT and AST ≤ 5 × ULN~  7. Total bilirubin \< 1.5 x ULN~  8. International Normalized Ratio (INR) and activated Partial Thromboplastin Time \[PTT\] within normal institutional limits~9. Male and female subjects must agree to use a highly reliable method of birth control (expected failure rate less than 5% per year) from the screening visit through 28 days after the last dose of study drug. Women of childbearing potential must have a negative pregnancy test at screening.~Exclusion Criteria:~1. Radiotherapy within 4 weeks or less prior to starting first veledimex dose~2. Subjects with clinically significant increased intracranial pressure or uncontrolled seizures.~3. Known immunosuppressive disease, autoimmune conditions, and /or chronic viral infections~4. Use of systemic antibacterials, antifungals or antivirals for the treatment of acute clinically significant infection within 2 weeks of first veledimex dose. Concomitant therapy for chronic infections is not allowed. Subjects must be afebrile prior to Ad-RTS-hIL-12 injection; only prophylactic antibiotic use is permitted perioperatively.~5. Use of enzyme-inducing anti-epileptic drugs (EIAED) within 7 days prior to the first dose of study drug.~6. Other concurrent clinically active malignant disease, requiring treatment, with the exception of non-melanoma cancers of the skin or carcinoma in-situ of the cervix or non-metastatic prostate cancer.~7. Nursing or pregnant females~8. Prior exposure to veledimex~9. Use of medications that induce, inhibit or are substrates of CYP450 3A4 within 7 days prior to the first veledimex dosing~10. Presence of any contra-indication for a neurosurgical procedure~11. Unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator or medical monitor, jeopardize the safety of a subject and/or their compliance with the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ad-RTS-hIL-12+veledimex (Type: EXPERIMENTAL): varying doses of intratumoral Ad-RTS-hIL-12 (INXN-2001) and oral veledimex (activator ligand).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete